CTLA4 and glioblastoma: This may be one of the reasons that antagonizing or blocking PD-1 and CTLA-4, which is well-recognized FDA-approved anticancer strategies aimed at improving T cell function in multiple malignancies, have shown only limited efficacy in GBM [9].